AUPH - Aurinia Pharma on with voclosporin exploratory trial for COVID-19 in kidney transplant patients

Aurinia Pharmaceuticals (AUPH) has announced the funding and initiation of an open-label exploratory trial evaluating its lead drug, voclosporin in kidney transplant recipients with COVID-19.This 56-day open-label investigator initiated trial is designed to evaluate the antiviral effects of voclosporin compared to tacrolimus in stable kidney transplant recipients who contracted SARS-CoV-2.Primary endpoint is the reduction in SARS-CoV-2 viral load over 56 days; the study will also assess predefined endpoints including time to 3-log reduction in viral load concentration, time to clinical recovery. Following the 56-day treatment period, there will be an extended safety follow-up of voclosporin treated patients for up to one year.

For further details see:

Aurinia Pharma on with voclosporin exploratory trial for COVID-19 in kidney transplant patients